Marc Lopez
YOU?
Author Swipe
View article: CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumors
CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumors Open
Chimeric antigen receptor T (CAR T) cells represent a promising therapeutic option for a variety of cancers, including solid tumors. Nectin-4 is a cell adhesion molecule expressed at different levels in many solid tumors, including breast …
View article: Table S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 2 shows the 6226 human plasma membrane and secreted proteins screened
View article: Table S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 5 shows the analysis of average Drug Antibody Ratio in monkey plasma
View article: Figure S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 2 shows IHC analysis of Nectin-4 expression on tumor tissue and human skin keratinocytes using 15A7.5
View article: Figure S6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 6 shows the analysis of nectin-4 expression in TNBC
View article: Figure S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 1 shows epitope mapping of humanized 15A7.5 to human nectin-4
View article: TableS6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
TableS6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 6 shows the summary of GLP toxicology study results
View article: Table S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 3 shows the affinities (Octet) of anti-hnectin-4 mAbs for monomeric and dimeric human nectin-4
View article: Figure S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 4 shows the analysis of ETx-22 infiltration in SUM190PT tumors
View article: Figure S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 3 shows the internalization of 15A7.5 and Ha22
View article: Table S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 1 shows apparent affinity of various chimeric mAbs and human HA22 anti-nectin-4 mAbs
View article: Table S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 4 shows the PK data of ETx-22 in Cynomolgus monkeys
View article: Figure S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 5 shows IHC analysis of ETx-22 infiltration and pharmacodynamic in SUM190PT tumors
View article: Table S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 5 shows the analysis of average Drug Antibody Ratio in monkey plasma
View article: Table S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 1 shows apparent affinity of various chimeric mAbs and human HA22 anti-nectin-4 mAbs
View article: TableS6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
TableS6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 6 shows the summary of GLP toxicology study results
View article: Figure 6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure 6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
In vivo efficacy of ETx-22 in SUM190 breast cancer cell line and PDX models. A, NSG mice (n = 5/group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel. At the indicated time (black arrowhead), three dif…
View article: Table S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 2 shows the 6226 human plasma membrane and secreted proteins screened
View article: Figure 4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure 4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
PK/PD characterization of ETx-22 ADC. NSG mice and PDX TNBC400-bearing NSG mice (n = 3 per time point) were injected intravenously when tumors averaged 150 mm3 (T0) with 10 mg/kg of ETx-22 (from humanized 15A7.5 mAb). At the indicated time…
View article: Figure S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 1 shows epitope mapping of humanized 15A7.5 to human nectin-4
View article: Figure 1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure 1 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Epitope characterization of the 15A7.5 antibody. A, The apparent EC50 ratio of chimeric 15A7.5 and 5A12.2 and human HA22 anti–nectin-4 mAbs on normal differentiated human keratinocytes vs. the SUM190 cell line. B, Specificity of chimeric m…
View article: Figure 2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure 2 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Differential recognition and activity of the 15A7.5 antibody. A, Quick scoring results for the staining of each tissue with murine 15A7.5 and 5A12.2 antibodies. Frozen tissue sections of high- and low-nectin-4–expressing CDX breast cancers…
View article: Figure S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 4 shows the analysis of ETx-22 infiltration in SUM190PT tumors
View article: Table S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 3 shows the affinities (Octet) of anti-hnectin-4 mAbs for monomeric and dimeric human nectin-4
View article: Figure S6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 6 shows the analysis of nectin-4 expression in TNBC
View article: Data from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Data from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Nectin-4 is a cell adhesion molecule expressed at various levels in many solid tumors, including urothelial cancer. As a means to reduce on-target skin toxicity observed with enfortumab vedotin (EV), an anti–nectin-4–monomethyl auristatin …
View article: Figure 3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure 3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Characterization of ETx-22 ADC. A, Schematic representation of ETx-22. B, Comparative HIC profile between the naked humanized 15A7.5 and ETx-22. C, DAR measure by LC/MS. Data indicate that cysteine from both light and heavy chains of the a…
View article: Figure S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure S3 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Figure 3 shows the internalization of 15A7.5 and Ha22
View article: Table S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Table S4 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
Supplementary Table 4 shows the PK data of ETx-22 in Cynomolgus monkeys
View article: Figure 5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Figure 5 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors Open
ETx-22 mechanism of action. PDX TNBC400-bearing NSG mice (n = 3 per time point) were injected intravenously when tumors averaged 150 mm3 (T0) with 10 mg/kg of ETx-22 (from humanized 15A7.5 mAb). At the indicated time points, animals were e…